¥1,693.00
0.36%
Tokyo, Oct 01, 03:16 pm JST.
ISIN
JP3336000009
Symbol
4536

Santen Pharmaceutical Stock price

¥1,694.50
-212.00 11.12% 1M
-154.50 8.36% 6M
+68.50 4.21% YTD
+52.50 3.20% 1Y
+345.00 25.57% 3Y
+153.50 9.96% 5Y
+201.50 13.50% 10Y
+1,094.50 182.42% 20Y
Tokyo, Closing price Thu, Oct 01 2026
+7.50 0.44%
ISIN
JP3336000009
Symbol
4536
Industry

Is Santen Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
¥543.7b
Enterprise Value
¥523.7b
Net debt
positive
Cash
¥81.5b
Shares outstanding
321.2m
Valuation (TTM | estimate)
P/E
14.0
P/S
1.9 | -
EV/Sales
1.8 | -
EV/FCF
18.8
P/B
1.8
Dividends
DPS
¥42.00
Yield 1Y | 5Y
2.5% | 2.5%
Growth 1Y | 5Y
10.5% | 5.6%
Payout 1Y | 3Y
33.3% | 36.9%
Increased
4 Years
Financials (TTM | estimate)
Revenue
¥291.8b | ¥307.1b
EBITDA
¥57.2b
EBIT
¥48.3b
Net Income
¥38.7b
Free Cash Flow
¥27.8b
Growth (TTM | estimate)
Revenue
-0.7% | 5.3%
EBITDA
14.8%
EBIT
17.1%
Net Income
22.8%
Free Cash Flow
-37.2%
Margin
Gross
59.2%
EBITDA
19.6%
EBIT
16.6%
Net
13.3%
Free Cash Flow
9.5%
Financial Health
Equity Ratio
70.2%
Return on Equity
12.6%
ROCE
14.3%
ROIC
13.6%
Debt/Equity
0.2
More
EPS
¥120.4
FCF per Share
¥86.7
Short interest
-
Employees
4k
Rev per Employee
¥75.8m

Santen Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Santen Pharmaceutical forecast:

9x Buy
69%
4x Hold
31%

Analyst Opinions

13 Analysts have issued a Santen Pharmaceutical forecast:

Buy
69%
Hold
31%

Financial data from Santen Pharmaceutical

Jun '26
+/-
%
291,844 291,844
1% 1%
100%
- Direct Costs 119,232 119,232
7% 7%
41%
172,612 172,612
4% 4%
59%
- Selling and Administrative Expenses 91,746 91,746
5% 5%
31%
- Research and Development Expense 26,226 26,226
6% 6%
9%
57,234 57,234
15% 15%
20%
- Depreciation and Amortization 8,894 8,894
4% 4%
3%
EBIT (Operating Income) EBIT 48,340 48,340
17% 17%
17%
Net Profit 38,686 38,686
23% 23%
13%

In millions JPY.

Don't miss a Thing! We will send you all news about Santen Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Santen Pharmaceutical Stock News

Neutral
Business Wire
●
4 days ago
MUMBAI, India & CINCINNATI--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, exclu...

Company Profile

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu and currently employs 3,744 full-time employees. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.

Head office Japan
CEO Mr. Ito
Employees 3,849
Website www.santen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today